Business Context and Reporting Period
This Form 8-K, dated July 14, 2026, reports that NextCure, Inc. (NXTC) has entered into a definitive merger agreement with Avere Therapeutics, Inc. The transaction is structured as a reverse merger where Avere will become the surviving entity, and NextCure will be renamed "Avere Therapeutics, Inc." The deal is expected to close in the third quarter of 2026, subject to stockholder approval and customary closing conditions.
Key Financial Metrics and Transaction Terms
- Financing: Avere has secured a private placement (PIPE) of approximately $320 million from institutional and accredited investors, contingent on the merger closing.
- Ownership Structure: On a pro forma basis, pre-Merger Avere stockholders (including PIPE investors) will own approximately 98.11% of the combined company, while pre-Merger NextCure stockholders will own approximately 1.89%.
- Consideration: Avere shareholders will receive NextCure common stock based on an exchange ratio. Beneficial ownership limitations apply, with excess shares converted to pre-funded warrants.
- Restructuring Costs: NextCure expects to incur one-time charges and cash expenditures of approximately $1.9 million in the quarter ending September 30, 2026, related to a workforce reduction plan.
- Termination Fees: NextCure may owe Avere $330,000, while Avere may owe NextCure $2,000,000 plus up to $750,000 in expense reimbursement upon termination under specified circumstances.
Material Changes and Operational Updates
NextCure announced significant strategic shifts regarding its legacy assets concurrent with the merger announcement:
- SIM0505 Program: NextCure will cease screening and enrolling new patients in the Phase 1 study for SIM0505 (an ADC targeting CDH6) in the U.S. and will not expand the program to Europe or Canada. The company intends to seek opportunities to partner, license, or monetize these rights.
- LNCB74 Collaboration: NextCure has opted out of continued cost-sharing for the LNCB74 program (an ADC targeting B7-H4) with LigaChem Biosciences. Discussions are ongoing regarding LigaChem continuing the trial as a sole developer.
- Workforce Reduction: A restructuring plan will result in a reduction in force affecting a substantial majority of NextCure's workforce by the end of the third quarter of 2026.
Guidance, Outlook, and Contingencies
- Contingent Value Rights (CVRs): Pre-Merger NextCure stockholders will receive one CVR for each share held. These rights entitle holders to 90% of gross proceeds from the license, sale, or disposition of NextCure's legacy assets (including SIM0505) during a specified term. There is no assurance that any payments will be made.
- Management Transition: Upon closing, the Board will consist of four members designated by Avere, and the combined company will be led by Avere's current President and CEO.
- Closing Conditions: The transaction requires approval from NextCure and Avere stockholders, Nasdaq listing approval, effectiveness of the Form S-4 registration statement, and receipt of at least $150 million in financing proceeds.
- Risks: Risks include failure to obtain stockholder approval, inability to complete financing, regulatory delays, and the uncertainty of realizing anticipated benefits from the merger.
Investor Verification Checklist
- Verify the final Exchange Ratio and the calculation of Parent Net Cash, as these determine the exact ownership percentage for NextCure shareholders.
- Review the upcoming Form S-4 proxy statement for detailed risk factors and the full terms of the merger agreement.
- Monitor the status of the $320 million PIPE financing and the $150 million minimum closing condition.
- Assess the potential value of the Contingent Value Rights (CVRs) based on the likelihood of monetizing the SIM0505 and LNCB74 assets.
- Confirm the timeline for the stockholder vote and the expected closing date in Q3 2026.